Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
September 12 2007 - 9:00AM
PR Newswire (US)
STEWARTVILLE, Minn., Sept. 12 /PRNewswire-FirstCall/ -- Rochester
Medical Corporation (NASDAQ:ROCM) announced today the publication
of results from a significant clinical study which further
demonstrates the effectiveness of the Company's proprietary
Infection Control Technology. The newly released September issue of
the "Annals of Internal Medicine" presents results of a randomized,
double-blind, controlled clinical trial involving 212 adult
patients at Denmark's Copenhagen Trauma Center. The study concluded
nitrofurazone-impregnated urinary catheters reduced the incidence
of catheter-associated bacteriuria and funguria in adult trauma
patients, reducing the need to change or prescribe new
antimicrobial therapy. The nitrofurazone-impregnated urinary
catheters used in the study were manufactured by Rochester Medical.
The control catheter was an all-silicone Foley catheter. The study
was conducted by Jakob Stensballe, PhD; Michael Tvede, MD; Dagnia
Looms, PhD; Freddy Knudsen Lippert, MD; Benny Dahl, DMSc; Else
Tonnesen, DMSc; and Lars Simon Rasmussen, PhD. Commenting on the
peer-reviewed publication of this clinical study, Rochester
Medical's CEO and President - Anthony J. Conway said, "This is more
good news in the ongoing effort to reduce serious infections in
hospitals around the world. There is now published data from the
United States, Denmark, South Korea, Spain, and Saudi Arabia
showing the effectiveness of our All Silicone Anti-Infection Foley
Catheters." Conway continued, "Hospital acquired infections are a
serious problem across the globe. In the United States alone it is
estimated these infections cause over 90,000 deaths a year. The
Center for Disease Control estimates 40% of all hospital acquired
infections are urinary tract infections resulting from Foley
catheterization. As further demonstrated by Dr. Stensballe and his
colleagues, these serious infections can be significantly reduced
by use of our advanced Release-NF(R) technology. Our team at
Rochester Medical is working vigorously to ensure clinicians
throughout the world get the message about how our
nitrofurazone-impregnated Foley catheters reduce infections. Some
major medical institutions already are embracing these benefits and
using the Rochester Medical Release-NF catheters." Conway also
noted, "Hospital acquired infections are coming under heightened
scrutiny, with the aim that increased attention will lead to
improvements and solutions. States are legislating that hospitals
publicly post data defining their incidence of hospital acquired
infections. Medicare recently finalized new reimbursement rules
that will eliminate payments to hospitals to cover the cost of
catheter-associated urinary tract infections. "We believe Rochester
Medical's All-Silicone Anti-Infection Foley catheters will play a
pivotal role in helping reduce these infections. While costs can be
significantly decreased, most importantly, serious illness can be
prevented. It is very gratifying to continue to see new scientific
studies that inform clinicians and reaffirm the effectiveness of
our products. Everyone at Rochester Medical is very proud and
motivated to be technology leaders in the crucial fight against
hospital acquired infections." This press release contains
forward-looking statements that involve risks and uncertainties,
including the uncertainty of estimated revenues and profits, as
well as the uncertainty of market acceptance of new product
introductions, the uncertainty of gaining new strategic
relationships or locating and capitalizing on strategic
opportunities, the uncertainty of timing of private label sales
revenues (particularly international customers), FDA and other
regulatory review and response times, and other risk factors listed
from time to time in the Company's SEC reports and filings,
including, without limitation, the section entitled "Risk Factors"
in the Company's Annual Report on Form 10-K for the year ended
September 30, 2006. Rochester Medical Corporation develops,
manufactures, and markets disposable medical catheters and devices
for urological and continence care applications. The Company
markets under its own Rochester Medical(R) brand and under existing
private label arrangements. For further information, please contact
Anthony J. Conway, President and Chief Executive Officer of
Rochester Medical Corporation at (507) 533-9600. More information
about Rochester Medical is available on its website at
http://www.rocm.com/. DATASOURCE: Rochester Medical Corporation
CONTACT: Anthony J. Conway, President and Chief Executive Officer
of Rochester Medical Corporation, +1-507-533-9600 Web site:
http://www.rocm.com/
Copyright
Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From May 2024 to Jun 2024
Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From Jun 2023 to Jun 2024